Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

Paz-Ares Luis; Hirsh Vera; Zhang Li; de Marinis Filippo; Yang James Chih-Hsin; Wakelee Heather A.; Seto Takashi; Wu Yi-Long; Novello Silvia; Juhasz Erszebet; Aren Osvaldo; Sun Yan; Schmelter Thomas; Ong Teng Jin; Pena Carol; Smit Egbert F.; Mok Tony S.

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

【24h】

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

机译：索拉非尼单药治疗非小细胞肺癌（MISSION）试验A阶段Sorafenib在经过2或3次既往治疗或复发或难治性非鳞状非小细胞肺癌患者中的III期，多中心，安慰剂对照试验方案

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line treatment in patients with non-small-cell lung cancer (NSCLC).

机译：简介：索拉非尼单一疗法已在II期临床试验中显示出作为非小细胞肺癌（NSCLC）患者的三线/四线治疗的益处。

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2015年第12期|共9页
作者
Paz-Ares Luis; Hirsh Vera; Zhang Li; de Marinis Filippo; Yang James Chih-Hsin; Wakelee Heather A.; Seto Takashi; Wu Yi-Long; Novello Silvia; Juhasz Erszebet; Aren Osvaldo; Sun Yan; Schmelter Thomas; Ong Teng Jin; Pena Carol; Smit Egbert F.; Mok Tony S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Non-small-cell lung cancer; Molecular targeted therapy; Sorafenib; KRAS mutation; EGFR mutation;

机译：非小细胞肺癌;分子靶向治疗;索拉非尼;KRAS突变;EGFR突变;

相似文献

外文文献
中文文献
专利

1. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens [J] . Paz-Ares Luis, Hirsh Vera, Zhang Li, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第12期

机译：索拉非尼单药治疗非小细胞肺癌（MISSION）试验A阶段Sorafenib在经过2或3次既往治疗或复发或难治性非鳞状非小细胞肺癌患者中的III期，多中心，安慰剂对照试验方案
2. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. [J] . Blumenschein GR Jr, Gatzemeier U, Fossella F Journal of Clinical Oncology . 2009,第26期

机译：II期单药索拉非尼在复发或难治性晚期非小细胞肺癌患者中的多中心，非对照试验。
3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. [J] . Fossella FV, DeVore R, Kerr RN, Journal of Clinical Oncology . 2000,第12期

机译：多西他赛与长春瑞滨或异环磷酰胺在之前接受过含铂化疗方案治疗的晚期非小细胞肺癌患者中的随机III期试验。 TAX 320非小细胞肺癌研究组。
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized Phase 3 Trial [O] . Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, 2016

机译：一线培美曲塞-顺铂再加吉非替尼维持治疗与吉非替尼单药治疗在晚期非鳞状非小细胞肺癌韩国患者中的耐受性和结果：一项随机3期试验的事后描述性亚组分析
7. Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial [O] . C. Gridelli, F. Perrone, C. Gallo, 2003

机译：高级非小细胞肺癌的老年患者化疗：多中心意大利肺癌在老年学习（Miles）III期随机试验

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

摘要

著录项

相似文献

相关主题

期刊订阅